Skip to main content

Advertisement

SpringerLink
Log in

Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Nivolumab, an anti-programmed cell death-1 (PD-1) antibody, has attracted increasing attention as a new treatment modality for gastric cancer. Herein, a case of acute kidney injury in a 66-year-old man with gastric cancer treated with nivolumab is presented. Kidney biopsy revealed severe acute interstitial nephritis and mild immunoglobulin A nephropathy. The cause of acute kidney injury was considered as acute interstitial nephritis because the main site of the lesion was the tubulointerstitium. Cessation of nivolumab and oral prednisolone administration rapidly improved the patient’s renal function. Nivolumab was then restarted without worsening of renal function. To the best of the authors knowledge, this is the first case in which reintroduction of nivolumab was successfully performed in a patient with gastric cancer. Further, the relevant literature was reviewed on nivolumab-induced acute interstitial nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

    Article  CAS  Google Scholar 

  2. Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

    Article  CAS  Google Scholar 

  3. Wang PF, Chen Y, Song SY et al (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730

    Article  Google Scholar 

  4. Kumar V, Chaudhary N, Garg M et al (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49

    Article  CAS  Google Scholar 

  5. Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571–588

    Article  CAS  Google Scholar 

  6. Manohar S, Kompotiatis P, Thongprayoon C et al (2019) Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant 34:108–117

    Article  CAS  Google Scholar 

  7. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546

    Article  CAS  Google Scholar 

  8. Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020–2031

    Article  CAS  Google Scholar 

  9. Sharma P, Callahan MK, Bono P et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17:1590–1598

    Article  CAS  Google Scholar 

  10. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375:1856–1867

    Article  Google Scholar 

  11. Kato K, Doki Y, Ura T et al. (2020) Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Sci 111(5):1676–1684

    Article  CAS  Google Scholar 

  12. Shirali AC, Perazella MA, Gettinger S (2016) Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68:287–291

    Article  CAS  Google Scholar 

  13. Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638–647

    Article  CAS  Google Scholar 

  14. Tanaka A, Ikinaga K, Kiyohara E et al (2017) Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient. J Dermatol 44:727–728

    Article  Google Scholar 

  15. Belliere J, Meyer N, Mazieres J et al (2016) Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer 115:1457–1461

    Article  CAS  Google Scholar 

  16. Escandon J, Peacock S, Trabolsi A et al (2017) Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer 5:3

    Article  Google Scholar 

  17. Bottlaender L, Breton AL, de Laforcade L et al (2017) Acute interstitial nephritis after sequential ipilumumab—nivolumab therapy of metastatic melanoma. J Immunother Cancer 5:57

    Article  Google Scholar 

  18. Koda R, Watanabe H, Tsuchida M et al (2018) Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol 19:48

    Article  Google Scholar 

  19. Nakatani Y, Kawakami H, Ichikawa M et al (2018) Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. Invest New Drugs 36:726–731

    Article  CAS  Google Scholar 

  20. Tabei A, Watanabe M, Ikeuchi H et al (2018) The analysis of renal infiltrating cells in acute tubulointerstitial nephritis induced by anti-PD-1 antibodies: a case report and review of the literature. Intern Med 57:3135–3139

    Article  Google Scholar 

  21. Georgianos PI, Vaios V, Leontaridou E et al (2019) Acute interstitial nephritis in a patient with non-small cell lung cancer under immunotherapy with nivolumab. Case Rep Nephrol 2019:3614980

    PubMed  PubMed Central  Google Scholar 

  22. Ryuzaki M, Tokuyama H, Uchiyama K et al (2019) Acute interstitial nephritis with karyomegalic epithelial cells after nivolumab treatment-two case reports. Clin Med Insights Case Rep 12:1179547619853647

    Article  Google Scholar 

  23. Hattahara K, Yamasaki T, Sawada A et al (2019) A case of late onset nivolumab-induced interstitial nephritis in a patient with metastatic renal cell carcinoma. Hinyokika Kiyo 65:157–161

    PubMed  Google Scholar 

  24. Oliveira DS, Mesquita JL, Garcia YDO et al (1992) Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma. Rev Assoc Med Bras 2019(65):934–936

    Google Scholar 

  25. Irifuku T, Satoh A, Tani H et al (2020) Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. CEN Case Rep 9:48–54

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Editage (www.editage.com) for English language editing.

Funding

This work was supported in part by the following grant: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Science Research (Grant numbers JP19K16718).

Author information

Authors and Affiliations

  1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan

    Qingjiang Hu, Hirofumi Hasuda, Yoko Zaitsu, Yasuo Tsuda, Yuichi Hisamatsu, Yuichiro Nakashima, Koji Ando, Yasue Kimura, Eiji Oki & Masaki Mori

  2. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Kenji Ueki & Akihiro Tsuchimoto

Authors
  1. Qingjiang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirofumi Hasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Ueki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Tsuchimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoko Zaitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuichi Hisamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuichiro Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koji Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasue Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eiji Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masaki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Qingjiang Hu and Hirofumi Hasuda. Kidney biopsy and diagnosis of acute interstitial nephritis were performed by Kenji Ueki and Akihiro Tsuchimoto (nephrologist). The first draft of the manuscript was written by Qingjiang Hu and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Eiji Oki.

Ethics declarations

Conflict of interest

Eiji Oki received honorarium from Ono Pharma.

Research involving human rights and animal participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Ethical approval

The authors declare that this study conformed to the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all human participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, Q., Hasuda, H., Ueki, K. et al. Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. Int Canc Conf J 9, 127–132 (2020). https://doi.org/10.1007/s13691-020-00418-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-020-00418-2

Keywords

Search

Navigation